What estrogen dominance actually means
The term estrogen dominance was introduced to describe a hormonal pattern that standard testing frequently misses: the relative excess of estrogen in relation to progesterone, regardless of whether estrogen itself is technically elevated.
To understand why this matters, it helps to understand the relationship between these two hormones across the cycle. In a well-functioning luteal phase, progesterone rises substantially after ovulation and acts as a counterbalance to estrogen's more stimulating effects on tissue growth, fluid retention, and nervous system excitability. This progesterone-estrogen balance is what makes the luteal phase feel manageable: progesterone's calming, stabilising influence via the GABA pathway moderates estrogen's more activating effects.
When progesterone is insufficient relative to estrogen, this counterbalancing effect is reduced. Estrogen's effects on tissue, fluid, and neurological function become relatively unopposed, producing the symptom cluster associated with estrogen dominance. Critically, this can occur when estrogen is genuinely elevated, when estrogen is normal but progesterone is low, or when both are declining in the late luteal phase but progesterone is falling disproportionately faster. All three scenarios produce the same relative imbalance and the same downstream symptoms.
The practical implication is that a test result showing estrogen within the normal reference range is not reassurance that estrogen dominance is absent. What matters is the ratio, and this is one of the reasons functional testing that measures both hormones simultaneously is more informative than standard testing that typically assesses one or the other in isolation.
The symptom profile
Estrogen dominance produces a recognisable symptom cluster that spans several systems, reflecting estrogen's wide-ranging effects on the body when its influence is not adequately balanced by progesterone.
Reproductive and cycle-related symptoms are often the most visible: worsening PMS (mood, physical, or both) in the one to two weeks before menstruation; heavier or more prolonged periods, reflecting estrogen's stimulating effect on uterine lining growth; breast tenderness and swelling, particularly in the premenstrual phase; and cycle irregularity or lengthening as the luteal phase becomes insufficient.
Fluid and body composition changes are also common: bloating and water retention, particularly in the second half of the cycle, driven by estrogen's effect on fluid balance in the absence of adequate progesterone; weight gain or difficulty shifting weight, particularly around the hips, thighs, and lower abdomen, which are estrogen-sensitive fat distribution sites; and a general sense of puffiness or heaviness that does not correlate with changes in diet or activity.
Mood and neurological symptoms reflect the progesterone-GABA deficit: anxiety and heightened nervous system reactivity, irritability, emotional volatility, and in some women, a wired and restless quality particularly in the evenings and the premenstrual phase. Sleep disruption in the luteal phase, specifically difficulty falling asleep or waking in the early hours, is common because progesterone's calming effects on the nervous system also support sleep onset and maintenance.
Other symptoms associated with the pattern include headaches or migraines that correlate with the premenstrual estrogen drop, fatigue (particularly in the luteal phase), and in some women, hair thinning, because the relatively elevated estrogen environment can affect the hair growth cycle.
What drives it in women who work in yachting
The primary driver of estrogen dominance in women under sustained occupational stress is progesterone suppression from chronic cortisol elevation, operating through the shared steroidogenic pathway described in detail in the earlier articles on female hormonal health.
This is the most important mechanistic point for crew: the pattern is not principally driven by too much estrogen. It is driven by too little progesterone. The body is not producing excess estrogen. It is producing insufficient progesterone to balance what estrogen is doing, because the shared pathway is diverting resources toward cortisol. This distinction matters because interventions aimed at reducing estrogen, while potentially relevant in some cases, are addressing the wrong end of the mechanism. The upstream driver that needs addressing is the cortisol load suppressing progesterone.
Several features of yachting life compound the pattern. Sustained cortisol elevation from irregular hours, the absence of work-rest separation, and the accumulated demand of a charter season all maintain the progesterone-suppressing cortisol load. Disrupted sleep reduces the body's capacity to regulate cortisol overnight, extending the suppressive effect. Nutritional gaps in magnesium, B6, and zinc, all nutrients involved in progesterone synthesis and cortisol regulation, reduce the system's capacity to maintain adequate progesterone output even in the absence of the cortisol competition.
The role of estrogen clearance
A second contributor to estrogen dominance that is independent of production is impaired estrogen clearance, the process by which used estrogen is metabolised and eliminated from the body.
Estrogen that has been used by cells needs to be broken down in the liver and cleared through the gut. This clearance process depends on adequate liver function, on the gut microbiome (specifically a subset of gut bacteria known as the estrobolome that metabolise estrogen prior to elimination), and on regular bowel transit. When any of these is compromised, estrogen that should be eliminated is instead reactivated and recirculated, adding to the total estrogenic load in the body.
For crew, several relevant factors affect estrogen clearance. Gut dysbiosis, which is common in the yachting population given the effects of stress, irregular eating patterns, and food quality variability, directly impairs the estrobolome's estrogen-metabolising function. Constipation or slow bowel transit, common when routine is disrupted, allows estrogen to be reabsorbed from the gut rather than eliminated. Liver function, which is responsible for the first stage of estrogen breakdown, can be compromised by elevated toxic load, alcohol, and certain medications, all of which have relevance in the on-board context.
This gut-liver-hormone axis means that gut health is directly relevant to estrogen dominance, not only in the context of digestive symptoms but as a mechanism that determines how effectively the body clears the estrogen it has already used.
Environmental contributors on board
A third contributor worth understanding is the environmental estrogenic load from compounds on board that can interact with estrogen receptors.
Xenoestrogens are chemicals found in plastics, certain cleaning products, pesticides, and some synthetic materials that mimic or interact with estrogen receptors in the body. On a vessel, relevant sources include plastic food storage and water containers (particularly when heated or degraded), certain cleaning chemicals used in the marine environment, antifouling compounds, and potentially the water supply depending on the vessel's source and treatment. These compounds do not act identically to endogenous estrogen, but they can add to the total estrogenic signal the body is managing, compounding the relative estrogen excess that is already present from progesterone suppression.
This is not an invitation to catastrophise about the on-board environment. The contribution from xenoestrogens is typically smaller than the contribution from progesterone suppression and impaired clearance. But it is worth being aware of as a real, if secondary, contributing factor, and it is one of the reasons that reducing unnecessary chemical exposure on board and prioritising glass or stainless steel over plastic for food and water storage are sensible practical measures alongside the hormonal interventions.
Belinda's Perspective
What four years of data taught me about ratio versus absolute levels
Every panel I have run since 2020 has shown a low Pg/E2 ratio. Not dramatically low estrogen, not dramatically high estrogen, but a consistently insufficient amount of progesterone relative to it. The ratio has been 31, then 20, then 21, then 29 across four consecutive tests. Each of those numbers is a different year, and each of them tells the same story.
What's striking, looking at those results side by side, is that my estradiol has generally stayed within what would be reported as a normal range. If I had only tested estrogen and seen a normal number, I would have had no obvious reason to investigate further. The problem was never the estrogen level in isolation. It was what the progesterone was doing relative to it, and that picture only becomes visible when you measure both and look at the ratio.
This is the practical reason I test the way I do and recommend testing the way I do: single-marker results without context can be genuinely misleading. A normal estradiol reading is not reassurance. A normal progesterone reading, taken at the wrong point in the cycle, is not reassurance. The pattern only becomes clear when you have both values, taken at the right time, and interpreted as a ratio rather than two separate numbers.
The other thing I notice in my data is that the ratio has shifted over time as I have been actively working on the pattern. The most recent reading of 29 is still below optimal, but it is higher than the low point of 20. That movement is the kind of evidence that tells me the interventions are doing something, even if the picture is not fully resolved. Progress that is visible in data is more motivating and more informative than progress you are trying to infer from symptoms alone, which is part of why I keep testing rather than stopping once things start to feel better.
